Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8JQZC)

• Drug Name: BNZ-1 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous T-cell lymphoma	2B01	Phase 2	[1]
T-cell leukaemia	2A90	Phase 2	[2]
Large granular lymphocytic leukemia	2A90.1	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID: DM8JQZC

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-15 (IL15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG-714	DM1T3KQ	Coeliac disease	DA95	Phase 2	[5]
SAR445877	DM91KZL	Aggressive cancer	2A00-2F9Z	Phase 2	[6]
N-803	DM4ZN8M	Human immunodeficiency virus infection	1C62	Phase 1	[7]
PF-07209960	DM1W90B	Aggressive cancer	2A00-2F9Z	Phase 1	[8]

Drug(s) Targeting Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldesleukin	DM4YMIS	Acute myelogenous leukaemia	2A41	Approved	[9]
Daclizumab	DM6OZQV	Aplastic anemia	3A70	Approved	[10]
AIR-insulin	DM8SYTE	Diabetic complication	5A2Y	Phase 3	[11]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[12]
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[13]
Carboxyamidotriazole orotate	DMN5JCX	Glioblastoma multiforme	2A00.0	Phase 2	[14]
Leuvectin	DM5LQEI	Melanoma	2C30	Phase 2	[15]
Human interleukin-2	DM0NJWG	Renal cell carcinoma	2C90	Phase 2	[16]
L19-IL-2 fusion protein	DMI2XP1	Lymphoma	2A80-2A86	Phase 2	[17]
Thymoctonan	DM4BLJM	Immune System disease	4A01-4B41	Phase 2	[18]

Drug(s) Targeting Interleukin-9 (IL9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MEDI-528	DMDYVN8	Asthma	CA23	Phase 2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-15 (IL15)	TTJFA35	IL15_HUMAN	Inhibitor	[4]
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Inhibitor	[4]
Interleukin-9 (IL9)	TT0JTFD	IL9_HUMAN	Inhibitor	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT03239392) A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [5] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [6] Clinical pipeline report, company report or official report of Sanofi
• [7] The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.
• [8] ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [11] The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
• [12] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [13] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [14] J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
• [15] Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
• [16] Clinical pipeline report, company report or official report of Immunservice.
• [17] National Cancer Institute Drug Dictionary (drug id 665656).
• [18] Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.
• [19] Clinical pipeline report, company report or official report of AstraZeneca (2009).